TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05881239

Intervention type: DEVICE
Intervention: AROMHA Brain Health Test
Description: The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.

Intervention type: DEVICE
Intervention: AROMHA Brain Health Test
Description: The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.

Intervention type: DEVICE
Intervention: AROMHA Brain Health Test
Description: The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.

Intervention type: DEVICE
Intervention: AROMHA Brain Health Test
Description: The AROMHA Brain Health Test is a self-administered, at-home smell test developed as a potential primary screen for identifying individuals at risk for developing Alzheimer's and as a means to follow disease progression in individuals without overt cognitive symptoms. The smell test device consists of five physical smell cards and a paired web-based app that directs participants on how to sample odors and asks them questions regarding what they have smelled. The 45-minute smell test battery includes measures of odor intensity, identification, memory, and discrimination.
Study: NCT04885647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhEPO
Description: YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhEPO
Description: YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhEPO
Description: YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YPEG-rhEPO
Description: YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.
Study: NCT06356623

Intervention type: OTHER
Intervention: 1
Description: this is not an intervention study
Study: NCT05891652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified thoracoabdominal nerve block through perichondrial approach
Description: Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
Study: NCT04715022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic acid solution (American Regent Laboratories Inc.)
Description: Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo (saline) will be administered
Study: NCT05492968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrin
Description: Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Patients in the phenylephrine group will receive a continuous infusion containing phenylephrine with a concentration of 0.2mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
Study: NCT04721288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active communication through Reboot application
Description: Access to active communication with the transplant care team through Reboot application based asynchronous messaging for non-urgent issues, as well as personalized clinical notifications.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Generic communication through Reboot application
Description: Access to generic messaging through Reboot application, and communication with the transplant care team through standard of care communication system.
Study: NCT06486584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency management payment for no disruptive behaviors each week.
Study: NCT05380141

Intervention type: BEHAVIORAL
Intervention: Individual patient interviews
Description: Two individual interviews, of one hour duration, will take place for each patient before the beginning of participating to the workshops and in the month following the end of the workshops.~They will be led by a psychologist and a nurse from the functional pain and palliative medicine unit of Necker Hospital and 3 questionnaires will be completed during each interview.
Study: NCT04692298

Intervention type: OTHER
Group type: OTHER
Intervention: pulses
Description: kidney beans, pinto beans, lentil, black-eyed pea and chickpea
Study: NCT05177783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuune health questionnaire
Description: Participants complete the Tuune contraceptive decision aid health questionnaire.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control health questionnaire
Description: Participants complete a standard physician intake health questionnaire.
Study: NCT05487820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IscAlert
Description: Insertion of a CO2- and temperature sensor(s) in the reconstructed flap.
Study: NCT05562141

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sample before induction, 1h after induction and 24h after the start of procedure

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sample before induction, 1h after induction and 24h after the start of procedure
Study: NCT05844072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with movement
Description: All participants will receive the MWM intervention with weight bearing ankle dorsiflexion range of motion measured prior to the intervention, immediately following the intervention, and 24 hours (+/- 3 hours) following the intervention. The participant will first place their foot on a 16-inch box to assist in performance of the intervention by the therapist. A licensed physical therapist (PT) will then stabilize the talus for a proper joint mobilization to be performed. The therapist will then mobilize the distal tib/fib in the posterior to anterior direction at end range DF reached through a forward lunge, using a Mulligan's mobilization belt around the distal tibia-fibula. The participant will perform 3 sets of 10 repetitions of the forward lunge and the PT will perform a bout of overpressure at end range during each repetition. Two other investigators will be on either side of participant to assist with balance during the intervention if needed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with movement
Description: All participants will receive the MWM intervention with weight bearing ankle dorsiflexion range of motion measured prior to the intervention, immediately following the intervention, and 24 hours (+/- 3 hours) following the intervention. The participant will first place their foot on a 16-inch box to assist in performance of the intervention by the therapist. A licensed physical therapist (PT) will then stabilize the talus for a proper joint mobilization to be performed. The therapist will then mobilize the distal tib/fib in the posterior to anterior direction at end range DF reached through a forward lunge, using a Mulligan's mobilization belt around the distal tibia-fibula. The participant will perform 3 sets of 10 repetitions of the forward lunge and the PT will perform a bout of overpressure at end range during each repetition. Two other investigators will be on either side of participant to assist with balance during the intervention if needed.
Study: NCT05530330

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet/Endothelial proteomics
Description: Samples taken will undergo a targeted proteomic investigation examining platelet/endothelial markers and associated extracellular vesicles
Study: NCT05281289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio-tape
Description: KT is comprised of a polymer elastic strand warped by 100% cotton fibers and designed to allow a longitudinal stretch of 55-60% of its resting length.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercise
Description: 15 seconds of passive stretching exercise for calf muscle followed by 30 seconds of rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instructions about dealing with calf cramps
Description: instructions about dealing with calf cramps by self low sustained stretch of calf muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instructions about dealing with calf cramps
Description: instructions about dealing with calf cramps by self low sustained stretch of calf muscle
Study: NCT00012662

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Self Management Education
Study: NCT06407609

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcuma and boswellia extracts plus low fodmap diet
Description: Low Foodmap diet + Curcuma and boswellia extracts both formulated in sunflower lecithin (Phytosome™) and processed with a strong commitment to sustainability

Intervention type: OTHER
Group type: OTHER
Intervention: Low Foodmap diet
Description: such as lactose or gluten free diet in the last 6 months
Study: NCT05331976

Intervention type: DIAGNOSTIC_TEST
Intervention: Proof Lab Test System
Description: Includes the Proof Lab Reader and the Proof Lab COVID-19 Test Kit containing: Proof Lab COVID-19 Test Cartridge, Sample Vial, Sample Swab, Exact Volume Transfer Pipette

Intervention type: DIAGNOSTIC_TEST
Intervention: Proof Lab Test System
Description: Includes the Proof Lab Reader and the Proof Lab COVID-19 Test Kit containing: Proof Lab COVID-19 Test Cartridge, Sample Vial, Sample Swab, Exact Volume Transfer Pipette
Study: NCT04128462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNK-6105
Description: L-Ornithine Phenylacetate for IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
Study: NCT03399838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: IN Dex for pediatric procedural sedation at the emergency department

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: po/pr midazolam as active comparator to dexmedetomidine for pediatric procedural sedation at the pediatric emergency department
Study: NCT05492422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central Executive Training (CET)
Description: Central Executive Training (CET)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central Executive Training (CET)
Description: Central Executive Training (CET)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central Executive Training (CET)
Description: Central Executive Training (CET)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central Executive Training (CET)
Description: Central Executive Training (CET)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Description: Behavioral Parent Training (BPT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Description: Behavioral Parent Training (BPT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Description: Behavioral Parent Training (BPT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Description: Behavioral Parent Training (BPT)
Study: NCT05275634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stander treatment
Description: Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stander treatment
Description: Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stander treatment
Description: Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stander treatment
Description: Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current with carrier frequency 2 KHz
Description: Interferential current treatment parameters will be as following; carrier frequency 2 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current with carrier frequency 4 KHz
Description: Interferential current treatment parameters will be as following; carrier frequency 4 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current with carrier frequency 8 KHz
Description: Interferential current treatment parameters will be as following; carrier frequency 8 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo interferential current
Description: Interferential current intensity will not be raised.
Study: NCT04657094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study: NCT06538298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Exercise Program with Gamification
Description: A comprehensive exercise program for 3 days a week for 6 weeks that utilizes non-contact boxing and gamification at moderate to vigorous intensity.
Study: NCT04964895

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Patients will fill in multiple questionnaires for this study :~EORTC quality of life questionnaire (QLQ) QLQ-C30, EORTC Shq22, Male Sexual Health Questionnaire (MSHQ) only for Men, FSFI (only for women)
Study: NCT06401837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian based acupressure application
Description: Acupoints include three points in hand: PC6 Neiguan, LI4 Hegu, HT7 Shenmen; two points in leg: SP6 Sanyinjiao \& ST36 Zusanli; and one point in back: DU14 Dazhui will be selected. The nurse will also teach patients and their caregiver how to apply acupressure on these acupoints. Self-administered acupressure application on the above acupoints will be performed and followed in the second week. A rehabilitation program and routine care will be scheduled as usual except for acupressure.
Study: NCT02844530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-epratuzumab tetraxetan
Description: The Primary objective is to compare the complete response rate (CR + CRp) after 2 injections of 370 MBq/m² of 90Y-epratuzumab tetraxetan RIT at day 1 and day 8 versus standard of care salvage chemotherapy regimens in adult CD22+ relapsed/refractory B-ALL.~A second RIT cycle (consolidation) will be allowed in the experimental group in case of response (CR or CRp).~From an ethical point of view, it will be also permitted to propose the RIT experimental treatment in the control group in case of treatment failure or relapse during the 6 months following inclusion. Follow-up will be also 12 months from the RIT for these patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy/ immunotherapy
Study: NCT05784766

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 30-second ECG using the Kardia Mobile
Description: 30-second ECG using the Kardia Mobile

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine care
Description: medical review
Study: NCT05227664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: AK117 at a dose of 45mg/kg via intravenous (IV) infusion on Days 1,8 ,15 and 22of each 28-day cycle until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: AK117 at a dose of 45mg/kg via intravenous (IV) infusion on Days 1,8 ,15 and 22of each 28-day cycle until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 at a dose of 20mg/kg via intravenous (IV) infusion on Days 1and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 at a dose of 20mg/kg via intravenous (IV) infusion on Days 1and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel at a starting dose of 90 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel at a starting dose of 90 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel at a starting dose of 90 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.